| D007328 |
Insulin |
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). |
Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin |
|
| D007657 |
Ketone Bodies |
The metabolic substances ACETONE; 3-HYDROXYBUTYRIC ACID; and acetoacetic acid (ACETOACETATES). They are produced in the liver and kidney during FATTY ACIDS oxidation and used as a source of energy by the heart, muscle and brain. |
Acetone Bodies,Bodies, Acetone,Bodies, Ketone |
|
| D008930 |
Mitochondria, Liver |
Mitochondria in hepatocytes. As in all mitochondria, there are an outer membrane and an inner membrane, together creating two separate mitochondrial compartments: the internal matrix space and a much narrower intermembrane space. In the liver mitochondrion, an estimated 67% of the total mitochondrial proteins is located in the matrix. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p343-4) |
Liver Mitochondria,Liver Mitochondrion,Mitochondrion, Liver |
|
| D009765 |
Obesity |
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). |
|
|
| D010477 |
Perfusion |
Treatment process involving the injection of fluid into an organ or tissue. |
Perfusions |
|
| D001786 |
Blood Glucose |
Glucose in blood. |
Blood Sugar,Glucose, Blood,Sugar, Blood |
|
| D002334 |
Carnitine O-Palmitoyltransferase |
An enzyme that catalyzes reversibly the conversion of palmitoyl-CoA to palmitoylcarnitine in the inner mitochondrial membrane. EC 2.3.1.21. |
Carnitine Palmitoyltransferase,CPT II,Carnitine Acyltransferase I,Carnitine Palmitoyltransferase I,Carnitine Palmitoyltransferase II,Palmitoylcarnitine Transferase,Palmitylcarnitine Acyltransferase,Acyltransferase I, Carnitine,Acyltransferase, Palmitylcarnitine,Carnitine O Palmitoyltransferase,II, Carnitine Palmitoyltransferase,O-Palmitoyltransferase, Carnitine,Palmitoyltransferase I, Carnitine,Palmitoyltransferase II, Carnitine,Palmitoyltransferase, Carnitine,Transferase, Palmitoylcarnitine |
|
| D003921 |
Diabetes Mellitus, Experimental |
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. |
Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete |
|
| D005934 |
Glucagon |
A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) |
Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor |
|
| D006946 |
Hyperinsulinism |
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS. |
Compensatory Hyperinsulinemia,Endogenous Hyperinsulinism,Exogenous Hyperinsulinism,Hyperinsulinemia,Hyperinsulinemia, Compensatory,Hyperinsulinism, Endogenous,Hyperinsulinism, Exogenous |
|